Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.


             
 

Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.

Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.

Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.

Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.

Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.



NAVIGATION


         

 

Results of a clinical study presented Thursday, Feb. 4 at the annual Triological Society meetings in Orlando, Fla., suggest a sterile barrier sheath system has distinct advantages over germicidal immersion processes used to prevent contamination of fiberoptic nasopharyngolaryngoscopes (flexible ENT scopes)…

 

Children who have cochlear implants (CI) rank their quality of life (QOL) equal to their normally hearing (NH) peers, indicates new research in the February 2010 issue of Otolaryngology - Head and Neck Surgery. A cochlear implant is an electronic device that restores partial hearing to the deaf. It is surgically implanted in the inner ear and activated by a device worn outside the ear…

 

It’s a ringing, a buzzing, a hissing or a clicking - and the patient is the only one who can hear it. Complicating matters, physicians can rarely pinpoint the source of tinnitus, a chronic ringing of the head or ears that can be as quiet as a whisper or as loud as a jackhammer.

 

Cochlear, the global leader in implantable hearing solutions, announced that the U.S. Food and Drug Administration (FDA) has approved the Nucleus((R) )5 System for adults and children with severe-to-profound hearing loss. Working with leading surgeons and audiologists worldwide, Cochlear has developed the most advanced technology including a smaller and thinner device with an unparalleled capability to deliver superior hearing performance and better user comfort.

 

PEAK Surgical, Inc. announced the launch of the PEAK((R)) PlasmaBlade TnA (Tonsil and Adenoid) tissue dissection device following 510(k) clearance from the U.S. Food and Drug Administration (FDA). This new product is indicated for cutting and coagulation of soft tissue during otolaryngology (ear, nose and throat [ENT]) surgery, including removal of the tonsils and adenoids.

 

Medtronic (NYSE: MDT) announced that results of a study published in the February issue of the Laryngoscope were favorable toward the use of Medtronic’s Straightshot® M4 Microdebrider for powered inferior turbinoplasty.

 

PEAK Surgical, Inc., announced the first use of its PEAK(R) Surgery System by surgeons in the European Union, where the innovative tissue dissection system received its CE Mark in January. Dr. Raul Pellini and Prof. Giuseppe Spriano, ear, nose and throat (ENT) surgeons at Istituti Fisioterapici Ospitalieri (National Cancer Institute) in Rome, performed head and neck surgeries in cancer patients using the PEAK PlasmaBlades(TM). Additionally, Prof.

 

The world’s largest ear, nose, and throat professional medical association, the American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS), has released a manual detailing best practices for the creation of new clinical practice guidelines. The manual is published as a supplement to the June issue of Otolaryngology - Head and Neck Surgery.

 

To look at Matthew Houdek, you could never tell he was born with virtually no left ear. A surgery at Loyola University Health System made it possible for Houdek to be fitted with a prosthetic ear that looks just like the real thing. Ear-nose-throat surgeon Dr. Sam Marzo implanted three small metal screws in the side of Houdek’s head. Each screw is fitted with a magnet, and magnetic attraction holds the prosthetic ear in place.

 

Respiratory Technology Corporation (dba Restech) announced today that its revolutionary Dx-pH Measurement System™ has received CE Mark approval, allowing introduction to the European Union and all countries recognizing the CE Mark. This approval from the European Union certifies Restech has met EU health, safety and environmental requirements that ensure consumer safety.




March 2010
Mon Tue Wed Thu Fri Sat Sun
« Feb    
1234567
891011121314
15161718192021
22232425262728
293031